地拉罗司治疗铁质积聚患者效果好吗？

It was the first oral iron chelator approved by the FDA for routine use in 2005 and is now available in more than 80 countries.

Oral suspensions and dispersible tablets marketed in the United States are approved for the treatment of chronic iron overload caused by blood transfusion in adult and pediatric patients 2 years and older, and chronic iron overload in patients with non-transfusion-dependent thalassemia (NTDT) syndrome 10 years and older. So, is deferasirox effective in treating patients with iron accumulation?

Therapeutic effects of deferasirox in treating iron accumulation:

To analyze the effect of deferasirox in the treatment of iron overload in children with β-thalassemia major.

Forty-six children with iron overload caused by β-thalassemia major who were treated from October 2015 to October 2017 were selected and divided into deferasirox group and deferoxamine group according to the random number table method, with 23 cases in each group.

The deferasirox group was treated with oral deferasirox, and the deferoxamine group was treated with subcutaneous pump deferoxamine. The disease control effects of the two groups after 1 year of medication were compared, as were serum iron (SI), ferritin (SF), brain natriuretic peptide (BNP), troponin I (cTnI) and urinary ferritin (UF) levels before and after medication, liver and heart MRI T2 values before and after medication, and adverse drug reactions.

Results: The disease control rate in the deferasirox group was 100%, which was higher than 78.26% in the deferoxamine group (word 2=5.610, P=0.018); after treatment, the serum SI, SF, BNP and cTnI levels in the deferasirox group were lower than those in the deferoxamine group, UF levels, liver and heart MRI The T2 values were all higher than those in the deferoxamine group, and the differences were statistically significant (P<0.05); the incidence of adverse reactions in the deferasirox group was lower than that in the deferoxamine group (P<0.05).

Conclusion: The treatment of iron overload in children with β-thalassemia major has better disease control effect than deferoxamine. It can effectively reduce serum SI, SF, BNP and cTnI levels, reduce the load of iron overload on the liver and heart, and the drug is safe.